↓ Skip to main content

Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials

Overview of attention for article published in Current Pharmaceutical Design, April 2012
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#26 of 2,661)
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
2 news outlets
twitter
27 tweeters
patent
1 patent

Citations

dimensions_citation
200 Dimensions

Readers on

mendeley
166 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials
Published in
Current Pharmaceutical Design, April 2012
DOI 10.2174/138161212799504803
Pubmed ID
Authors

Alexios S. Antonopoulos, Marios Margaritis, Regent Lee, Keith Channon, Charalambos Antoniades

Abstract

Ample evidence exists in support of the potent anti-inflammatory properties of statins. In cell studies and animal models statins exert beneficial cardiovascular effects. By inhibiting intracellular isoprenoids formation, statins suppress vascular and myocardial inflammation, favorably modulate vascular and myocardial redox state and improve nitric oxide bioavailability. Randomized clinical trials have demonstrated that further to their lipid lowering effects, statins are useful in the primary and secondary prevention of coronary heart disease (CHD) due to their anti-inflammatory potential. The landmark JUPITER trial suggested that in subjects without CHD, suppression of low-grade inflammation by statins improves clinical outcome. However, recent trials have failed to document any clinical benefit with statins in high risk groups, such in heart failure or chronic kidney disease patients. In this review, we aim to summarize the existing evidence on statins as an anti-inflammatory agent in atherogenesis. We describe the molecular mechanisms responsible for the antiinflammatory effects of statins, as well as clinical data on the non lipid-lowering, anti-inflammatory effects of statins on cardiovascular outcomes. Lastly, the controversy of the recent large randomized clinical trials and the issue of statin withdrawal are also discussed.

Twitter Demographics

The data shown below were collected from the profiles of 27 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 166 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Iran, Islamic Republic of 3 2%
United Kingdom 2 1%
Brazil 1 <1%
Italy 1 <1%
Switzerland 1 <1%
Japan 1 <1%
Germany 1 <1%
Colombia 1 <1%
Greece 1 <1%
Other 0 0%
Unknown 154 93%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 37 22%
Researcher 29 17%
Student > Bachelor 28 17%
Student > Master 21 13%
Unspecified 13 8%
Other 38 23%
Readers by discipline Count As %
Medicine and Dentistry 66 40%
Unspecified 27 16%
Agricultural and Biological Sciences 26 16%
Pharmacology, Toxicology and Pharmaceutical Science 14 8%
Biochemistry, Genetics and Molecular Biology 13 8%
Other 20 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 37. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 September 2019.
All research outputs
#466,555
of 13,528,070 outputs
Outputs from Current Pharmaceutical Design
#26
of 2,661 outputs
Outputs of similar age
#3,480
of 122,027 outputs
Outputs of similar age from Current Pharmaceutical Design
#1
of 27 outputs
Altmetric has tracked 13,528,070 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,661 research outputs from this source. They receive a mean Attention Score of 4.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 122,027 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.